Can Özlü: Can the HALP Score Help Identify Thrombotic Risk in Myeloproliferative Neoplasms?
Can Özlü, General Manager at CAS Industrial Health Products Trading Ltd. Co., Associate Professor at Kütahya Health Sciences University, Special Education Specialist at KSBÜ Society for Computational Sciences and Innovative Technology in Healthcare, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Medical Records, adding:
“Can routine laboratory data help us recognize thrombotic risk in myeloproliferative neoplasms more clearly?
Our new study, now available in the official Medical Records archive, evaluated the HALP score and systemic immune-inflammation index (SII) in 93 patients with polycythemia vera or essential thrombocythemia.
Thrombosis occurred in 27 patients. HALP scores were lower in patients with thrombosis, and HALP showed moderate discrimination in ROC analysis (AUC 0.723). At a cutoff of 32.2, sensitivity was 70.6% and specificity 59.4%. SII, by contrast, did not reach statistical significance.
The clinically important message is one of possibility, not proof. This was a retrospective, single-center study with a limited sample, so HALP should not replace established risk models or guide treatment on its own. It is a practical, inexpensive candidate marker that deserves prospective and external validation.
I thank my co-authors Cumali Yalçın, Aycan Acet, Aysun Gönderen and Ezgi Feyza Aydın for this collaboration.
What validation would you consider essential before a composite laboratory score could influence clinical decisions?”
Title: Utilization of HALP and Systemic Immune-Inflammation Index for Thrombotic Risk in Polycythemia Vera and Essential Thrombocythemia
Authors: Cumali Yalcin, Aycan Acet, Aysun Gonderen, Ezgi Feyza Aydin, Can Ozlu
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 9, 2026, 13:06Ohanna Cavalcanti Bezerra: Why Does DVT Lead to PE in Some Patients but Not Others?
-
Sep 9, 2026, 13:04Usman Shehzad: Transforming Patient Lives with INR Self-Testing
-
Sep 9, 2026, 13:02Edward Lee Carter: Provoked VTE May Not Tell the Whole Story About Recurrence Risk
-
Sep 9, 2026, 13:01Danielle Charissa: Functional Genomics Reveals a Causal TWIST1 Variant in Cardiovascular Disease
-
Sep 9, 2026, 12:59Hussnain Javaid: MCQ – Based on the Recent BSH’s Guideline on TTP Diagnosis
-
Sep 9, 2026, 12:58Nicolas Federico Renna: When Biomarkers Fall but Cardiovascular Events Do Not
-
Sep 9, 2026, 12:01Raghavendra Rao: Varicose Veins and Easy Bruising – Is There a Link?
-
Sep 9, 2026, 11:03Abdul Muqtadir Abbasi: Why Platelets Go Low in ITP?
-
Sep 9, 2026, 10:40Katrina Snow: Non-Invasive Fetal Blood Group Genotyping Is Coming to Ontario